Open AccessAquagenic Urticaria Treated with Omalizumab
Author(s) -
Yejin Ha,
So Yeong Jung,
SeungGeun Lee,
Chan Sun Park
Publication year - 2021
Publication title -
the korean journal of medicine
Language(s) - English
Resource type - Journals
eISSN - 2289-0769
pISSN - 1738-9364
DOI - 10.3904/kjm.2021.96.4.363
Subject(s) - omalizumab , dermatology , medicine , chronic urticaria , refractory (planetary science) , immunoglobulin e , immunology , physics , astrobiology , antibody
Aquagenic urticaria is a rare form of physical urticaria in which a 1-2 mm wheal is produced by contact with water. Treatment options include antihistamines, ultraviolet monotherapy, topical barrier creams, and acetylcholine antagonists. Despite these pharmacologic measures, the symptoms are frequently refractory to therapy. Aquagenic urticaria lowers the patient’s quality of life and causes daily discomfort. Recently, a patient with aquagenic urticaria treated with omalizumab was reported. Here, we describe a 22-year-old man with a 3-year history of aquagenic urticaria confirmed by a water immersion test. Because he showed no improvement with antihistamines, the patient began omalizumab treatment and demonstrated an excellent response. This case provides new information for clinicians.